TBG Diagnostics
TBG Diagnostics Ltd specializes in the research, development, and manufacturing of molecular diagnostics kits, instruments, and related services. The company focuses on the InVitro Diagnostics segment, which includes research on biological drugs and the retail and wholesale distribution of veterinary pharmaceuticals, primarily operating in Taiwan and China. Additionally, TBG Diagnostics operates a molecular typing laboratory that offers a range of HLA-typing services, certified by the American Society of Histocompatibility and Immunology. Through its diverse offerings, TBG Diagnostics aims to enhance diagnostic capabilities and contribute to advancements in healthcare.
Progen Pharmaceuticals, Inc. develops pharmaceutical products for the treatment of anti-proliferation and cancer therapeutics. The company's products are also used for the treatment of various diseases, including age-related macular degeneration, infectious diseases, inflammatory diseases, and vascular hyperplasia. Progen Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Redwood City, California. Progen Pharmaceuticals, Inc. was formerly known as CellGate, Inc. As a result of the acquisition of Cellgate, Inc. by Progen Pharmaceuticals Limited, Cellgate's name was changed. As of February 7, 2008, Progen Pharmaceuticals, Inc. operates as a subsidiary of Progen Pharmaceuticals Limited (ASX: PGL).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.